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512Safety of supervised exercise therapy in patients with
intermittent claudication
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Marc R. M. Scheltinga, MD, PhD,c,d Joep A. W. Teijink, MD, PhD,a,b and Ron J. G. Peters, MD, PhD,e
Eindhoven, Maastricht, Veldhoven, and Amsterdam, The Netherlands
Background: Supervised exercise therapy (SET) is recommended as the primary treatment for patients with intermittent
claudication (IC). However, there is concern regarding the safety of performing SET because IC patients are at risk for
untoward cardiovascular events. The Dutch physical therapy guideline advocates cardiac exercise testing before SET, if
indicated. Perceived uncertainties concerning safety may contribute to the underuse of SET in daily practice. The
objective of this review was to analyze the safety of supervised exercise training in patients with IC.
Methods: Two authors independently studied clinical trials investigating SET. Data were obtained from MEDLINE,
EMBASE, and The Cochrane Central Register of Controlled Trials. Complication rates were calculated and expressed as
numberof events pernumberof patient-hours.Theusefulness of cardiac screeningbefore SETwas evaluated in a subanalysis.
Results: Our search strategy revealed 2703 abstracts. We selected 121 articles, of which 74 met the inclusion criteria.
Studies represent 82,725 hours of training in 2876 IC patients. Eight adverse events were reported, six of cardiac and two
of noncardiac origin, resulting in an all-cause complication rate of one event per 10,340 patient-hours.
Conclusions: SET can safely be prescribed in patients with IC because an exceedingly low all-cause complication rate was
found. Routine cardiac screening before commencing SET is not required. Our results may diminish perceived
uncertainties regarding safety and will possibly increase the use of SET in daily practice. (J Vasc Surg 2015;61:512-8.)Some 50% to 80% of patients with peripheral arterial
disease (PAD) are symptomatic with intermittent claudica-
tion (IC).1 IC is deﬁned as muscle discomfort in the lower
limb(s) elicited by exercise that resolves after a short period
of rest.1 IC is associated with signiﬁcant disability, reduced
quality of life,2,3 and an increased risk of death.4 A recent
study found a signiﬁcant difference in survival when pat-
ients with and without PAD were compared; for instance,
the all-cause and cardiovascular mortality rates were 24%
and 7.7% in patients with PAD vs 9.5% and 2.4% in patients
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://dx.doi.org/10.1016/j.jvs.2014.08.070The unfavorable prognosis associated with PAD is domi-
nated by the concomitant presence of cerebral and coronary
artery disease (CAD) due to generally accepted risk factors
(smoking, hypertension, diabetes mellitus, hyperlipid-
emia).6-8 The estimated overall prevalence of atherosclerotic
CAD in PAD is 72%, with an obstructive nature in 61% to
98% in certain subgroups.9,10 The Quebec Cardiovascular
Study reported that the risk of fatal and nonfatal cardiovas-
cular events in men with IC was twice as high compared
with men without known cardiovascular disease.11
International guidelines state that treatment of IC
should consist of a multimodal approach that includes car-
diovascular risk reduction combined with symptomatic
treatment.1,7 First-choice symptomatic treatment, demon-
strated by Level I evidence, is daily supervised exercise ther-
apy (SET).12-17 Apart from symptomatic improvement, a
12-week SET program also reduced overall cardiovascular
mortality by 52% and morbidity by 30%.18 Although it is
generally accepted that SET should be part of the initial
treatment for each patient with IC, this therapeutic tool
is seriously underused in clinical practice.19-21 A study
among surgeons in the United Kingdom revealed that
only 24% of IC patients had access to SET.21 Moreover,
a large variation was found in the proportion of eligible pat-
ients referred to such an exercise program.
Lack of knowledge on referral criteria was also
observed in a recent nationwide survey among Dutch
Fig. Flow chart of study selection. *Deﬁned as1missingdata on complications during supervised exercise training (SET),2
incomplete data on reasons for dropout, or3 nonresponse on e-mail request as a ﬁnal attempt to obtain information.
Table I. Demographic characteristics (N ¼ 2876)
Characteristics Mean (range) or No.
Age, years 64 (54-76)
Men, % 71 (30-100)
Countrya
Europe 44
Asia 2
North America 18
South America 4
Oceania 5
Africa 1
aNumber of studies performed in listed continents.
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Volume 61, Number 2 Gommans et al 513vascular surgeons. Approximately 70% of the interviewed
surgeons were convinced that coexisting cardiopulmonary
comorbidity or aortoiliac stenosis or occlusion, or both,
were relative contraindications for participation in a SET
program.20 These doubts are strengthened by a worry
among physical therapists providing SET because they
fear the onset of cardiovascular events that may possibly
occur during exercise. Moreover, physical therapy guide-
lines advocate cardiac screening before SET,22 although
evidence to support such a strategy is currently lacking.
SET is often described as well tolerated, and two studies re-
ported cardiovascular complications were rare.23,24 The
aim of the present study was to analyze the safety of SET
in patients with IC in terms of onset of untoward (cardio-
vascular) events.
METHODS
Participants. We included studies that investigated the
role of SET in patients diagnosed with IC (Fontaine II/
Rutherford 1-3).
Types of studies. Eligible studies examined SET alone
or in a comparison model with other treatments such as
endovascular treatment, vasoactive medication, or non-
SET. Randomized and nonrandomized studies were
included. Although treadmill walking is considered an
important component of a SET program, uncertainty
remains regarding the most effective content of such a
program.25 All types of SET programs were therefore
included (eg, pole-striding and strength training). The
search was limited to studies in humans and articles written
in Dutch, German, or English. No limitation to date of
publication was considered.
Search strategy. We performed a search inMEDLINE
(1966 to June 2013) using the following Medical Subject
Heading terms: “peripheral arterial diseases,” “peripheral
vascular diseases,” “intermittent claudication,” “peripheral
arter* occlus*,” “claudica*,” “isch* limb*,” “exercise,”
“exercise therapy,” “exercise movement techniques,”“walk*,” “runni*,” “exerc*,” “train*,” and “treadmill.”
Additional articles were found bymatching a previous search
of Cochrane Central Register of Controlled Trials (1966 to
September 2012) and EMBASE (1974 to June 2013) and
removing duplicates. We also searched bibliographies of
included articles. After screening titles and abstracts, two
reviewers (L.G., H.F.) independently selected articles, based
on a full-text evaluation. Disagreement between reviewers
was discussed and resolved by consensus.
Data extraction and management. Two authors
(L.G., H.F.) used a standardized data extraction form
to extract the following data: details of the study population,
country, research setting, number of participants, number of
dropouts/lost to follow-up, reasons for dropout, age,
gender, inclusion and exclusion criteria, description of the
supervised exercise protocol, frequency, duration, content,
all types of reported complications related to SET, and the
use of cardiopulmonary exercise testing (CPET). To exclude
the potential inﬂuence of medication, only results obtained
from participants in the placebo control group of random-
ized controlled trials were included.
If studies did not explicitly report possible occurrence of
adverse events, we used information on the number of drop-
outs and reasons for dropout. Studies that contained
Table II. Characteristics of included studiesa
Author Year Country No.
Mean
age,
years Male, %
Supervised exercise program
Adverse events
Duration,
weeks
Frequencyb
(per week)
Content
(main component)
Andreozzi 2008 Italy 74 65 91 6 3 Treadmill None
Andreozzi 2007 Italy 22 67 100 6 3 Treadmill None
Arosio 2001 Italy 12 65 NR 2 7 Treadmill None
Badger 2007 Ireland 8 70 NR 6 2 Treadmill None
Beckitt 2012 UK 27 68 98 12 2 Circuit training None
Beckitt 2012 UK 42 66 69 12 2 Circuit training None
Bendermacher 2007 Netherlands 93 64 63 24 2.5 Treadmill None
Cachovan 1994 Germany 21 62 NR 4 5 Treadmill None
Carlon 2008 Italy 41 NR NR 12 3 Treadmill None
Cheetham 2004 UK 30 65 NR 24 1 Circuit training None
Ciuffeti 1994 Italy 15 56 >99 12 2 Mixed exercises None
Collins 2005 USA 27 70 98 24 3 Pole striding None
Collins 2012 USA 103 66 93 24 3 Treadmill þ pole
striding
None
Collins 2011 USA 72 66 75 24 1 Walking None
Cousin 2011 France 31 56c 97 4 5 Treadmill None
Crowther 2008 USA 11 71 50 52 3 Treadmill None
Degischer 2002 Switzerland 46 68 NR 12 1 Treadmill None
Franz 2010 USA 101 72 46 12 3 Treadmill None
Gardner 2005 USA 77 NR 88 24 3 Treadmill None
Gardner 2011 USA 40 66 45 12 3 Treadmill None
Gardner 2002 USA 31 68 NR 24 3 Treadmill None
Gardner 2012 USA 106 67 86 24 3 Treadmill None
Gibelline 2000 Italy 20 65 99 4 5 Treadmill None
Greenhalgh 2008 UK 127 65 63 24 1 Treadmill None
Grizzo Cucato 2011 Brazil 34 67 60 12 2 Circuit training None
Hiatt 1996 USA 29 61 NR 20 3 Treadmill None
Hiatt 1990 USA 25 67 100 12 3 Treadmill None
Hiatt 2011 USA 30 66 83 24 0.29 Treadmill None
Hobbs 2007 UK 9 NR 78 12 2 Circuit training None
Hodges 2008 UK 14 67 NR 12 2 Treadmill None
Jones 2012 USA 30 69 60 12 3 Treadmill None
Kakkos 2005 UK 12 61 92 6 3 Treadmill None
Kiesewetter 1987 Germany 15 64 70 6 5 Treadmill None
Krause 1978 Germany 63 66 77 6 5 Mixed exercise None
Krause 1976 Germany 55 65 74 6 5 Mixed exercise 1 myocardial
infarction
Kruidenier 2011 Netherlands 35 67 63 24 2.5 Treadmill None
Lee 2007 UK 33 68 67 12 3 Circuit training None
Leicht 2011 Australia 12 64 50 52 3 Treadmill None
Lundgren 1989 Sweden 25 61 79 24 2 Mixed exercise None
Mannarino 1991 Italy 10 63 67 24 2 Treadmill None
Mannarino 1989 Italy 8 69 75 24 2 Treadmill None
Martinez 2009 Israel 84 69 66 37 2 Treadmill None
Mazari 2012 UK 60 69 62 12 3 Circuit training None
McDermott 2009 USA 103 NR 52 24 3 Treadmill 1 cardiac arrest;
1 chest pain
McDermott 2004 USA 24 70 50 12 3 Treadmill 1 heart
arrhythmias;
1 chest pain
McGuigan 2001 Australia 11 61 36 24 3 Circuit training None
Mika 2011 Poland 34 64 90 12 3 Treadmill None
Mika 2005 Poland 49 64 85 12 3 Treadmill None
Murphy 2012 USA þ Canada 43 69 49 26 3 Treadmill None
Nawaz 2001 UK 52 69 83 6 2 Treadmill None
Ng 2005 UK 16 NR 63 8 3 Walking None
Nicolaï 2010 Netherlands 202 62 67 52 2.5 Treadmill None
Parr 2009 South-Africa 17 68 30 6 3 Strength training None
Patterson 1997 USA 27 NR 53 12 3 Mixed exercise None
Perkins 1996 UK 26 65 NR 24 2 Mixed exercise None
Regensteiner 1997 USA 10 NR NR 12 3 Treadmill None
(Continued on next page)
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Table II. Continued.
Author Year Country No.
Mean
age,
years Male, %
Supervised exercise program
Adverse events
Duration,
weeks
Frequencyb
(per week)
Content
(main component)
Ritti Dias 2010 Brazil 34 62 67 12 2 Strength training None
Sanderson 2006 Australia 28 66 39 6 3 Treadmill None
Savage 2001 USA 11 68 68 12 3 Treadmill None
Saxton 2011 UK 71 60 79 24 2 Treadmill None
Schefﬂer 1994 Germany 15 69 70 4 5 Treadmill þ
walking
None
Schlager 2011 Austria 20 66 65 24 2 Treadmill None
Slørdahl 2005 Norway 18 66 NR 8 3 Treadmill None
Spronk 2009 Netherlands 75 68 52 24 2 Treadmill None
Stewart 2008 UK 30 62 67 12 2 Circuit training None
Streminski 1992 Germany 30 69 67 4 5 Treadmill 1 increased
heart rate þ
dyspnea; 1
worsening of
osteoarthritis;
1 ischialgia
Tew 2009 UK 27 69 NR 12 2 Arm ergometry None
Tisi 1997 UK 22 67 69 4 1 Mixed exercise None
Treat-Jacobson 2009 USA 37 76 33 12 3 Treadmill or arm
ergometry
None
Tsai 2002 Taiwan 27 68 81 12 3 Treadmill None
Villemur 2011 France 11 72 NR 2 5 Treadmill None
Wang 2007 Australia 22 54 100 12 3 Treadmill None
Winterfeld 1983 Germany 17 64 NR 12 2 Circuit training None
Wood 2006 Australia 7 65 72 6 3 Treadmill None
NR, Not reported.
aThe reference list for the studies is in the Supplementary Appendix (online only).
bRecalculated to frequency per week.
cMedian age.
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was sent to authors who reported unclear data regarding
SET-related complications or reasons for dropout to obtain
details on the occurrence of untoward events. Studies of au-
thors who did not respond to this e-mail were also excluded.
Statistical analysis and data synthesis. Data were
analyzed using SPSS 18.0 software (SPSS Inc, Chicago,
Ill). The total number of patient-hours was calculated as
the number of patients multiplied by the number of
training sessions corrected for the mean duration of each
session. When information on the exact duration of
training sessions was lacking, an approximation of 30 min-
utes was assumed. Adverse events were characterized as
cardiac or noncardiac. The role of cardiac screening was
studied by performing a subanalysis. We calculated sepa-
rated event rates based on the use of CPET before SET.
RESULTS
Study selection. We identiﬁed 2703 records resulting
in the study of 121 relevant articles. Overall, 74 studies
(Supplementary Appendix, online only) with a total of
2876 IC patients met inclusion criteria (Fig). Patients
represented 82,725 patient-hours of SET.
Study characteristics. Most of the SET studies were
performed in Western Europe and North America. Mean
patient age ranged from 54 to 76 years, and more menthan women participated (Table I). Frequently reported
patient exclusion criteria were IC presenting with pain at
rest, critical ischemia, exercise capacity limited by symptoms
of angina, congestive heart failure, chronic obstructive
pulmonary disease, arthritis, and poorly controlled hyper-
tension. Exercise programs consisted of treadmill training
(n ¼ 49), mixed exercise therapy (n ¼ 8), circuit training
(n¼ 11), strength training (n¼ 2), arm ergometry (n¼ 2),
or pole-striding (n ¼ 2). Duration of the exercise programs
ranged from 2 weeks to 12 months. Training frequencies
varied from one to seven times a week, and 30 to 120 mi-
nutes per day (Table II).
Main outcome measurement. Potential adverse events
were explicitly reported in 35 of the 74 studies. Another 32
studies reported no dropouts or dropouts without medical
cause. The remaining seven studies were included after posi-
tive e-mail conformation. Eight adverse events of cardiac
(n ¼ 6) and noncardiac (n ¼ 2) origin were reported
(Table III). One fatal adverse event was reported. The total
all-cause event rate was one event per 10,340 patient-hours.
Total cardiac and noncardiac event rates were one per 13,788
and one per 41,363 patient-hours, respectively (Table IV).
Subanalysis on cardiac screening. Of 28 studies
(26,790 patient-hours of SET [32%]) that included car-
diac screening before SET was initiated, 23 used electro-
cardiography registration. Four of the eight adverse events
Table III. Overview of adverse events occurred during
supervised exercise training (SET)
Event No. (N ¼ 8)
Heart arrhythmias 1
Angina pectoris 2
Cardiac arresta 1
Myocardial infarctionb 1
Increased heart rate and dyspneac 1
Worsening of osteoarthritisc 1
Ischialgiac 1
aSuccessfully resuscitated.
bFatal outcome.
cNo treatment needed.
Table IV. Complication rates during supervised exercise
training (SET)
Complication No. of events Complication ratesa
All-cause 8 1:10,340
Cardiac 6 1:13,788
Noncardiac 2 1:41,363
aExpressed as 1 event per number of patient-training hours.
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including a fatal myocardial infarction, were found in the
46 remaining studies that did not included cardiac
screening (55,935 patient-hours of SET [68%]). Six studies
reported results of 1703 CPETs before SET inclusion.
Abnormal CPET ﬁndings resulted in 59 patients (3.5%)
being excluded from SET participation.
DISCUSSION
The aim of this review was to identify SET-related
complications in patients with IC as a means to determine
its safety. To our knowledge, this is the ﬁrst study address-
ing the safety issue of SET. Eight complications were
described during >80,000 patient-hours of SET, resulting
in an all-cause complication rate of one event in 10,340
patient-hours. Therefore, the risk of complications during
SET is considered exceedingly low. Focusing on the two
major cardiac complications, an even lower event rate of
one event in 41,362 patient-hours was calculated. These
results are in line with a prospective registry on complica-
tions during exercise for cardiac rehabilitation reporting
an almost similar rate of one event per 49,565 patient-
hours.26 Moreover, these rates may even be considered
relatively high because events that were reported in studies
from >30 years ago were also included. Medical treatment
has greatly improved the overall prognosis, potentially
resulting in even lower current event rates.
CPET has been used for >60 years for risk stratiﬁcation
in patients with heart diseases,27 but this technique is no
longer recommended as a screening tool for myocardial
ischemia in people without known CAD, as suggested by
a recent guideline of The National Institute for Health
and Clinical Excellence.28 Prediction of a future severe car-
diac event during exercise is very difﬁcult, if not impos-
sible.26 In the present review, 28 studies (32% of total
patient-hours) included cardiac screening, but because an
equal number of adverse events (n¼ 4) was found in studies
with or without cardiac screening, the results may indicate
that cardiac screening in IC patients is indeed not useful.
However, by the observational and retrospective design of
our study, ﬁrm conclusions cannot be drawn. Yet, given
the very low complication rate, cardiac screening as a tool
for a safe execution of SET seems clinically irrelevant.There is also a downside using CPET as a screening
technique. As all screening tests do, CPET also inherently
carries a risk of false-positive testing; for instance, a 15%
false-positive rate is observed in patients with chest pain,29
whereas this percentage is even higher in asymptomatic pat-
ients.30 A false-positive test result will incorrectly and unnec-
essary exclude IC patients from a ﬁrst-choice treatment.1,7
In addition, false-positive results may lead to unnecessary
(invasive) interventions (eg, coronary angiography) with
accompanied morbidity, mortality, and costs. The risk of a
false-negative test result after CPET is also present, as illus-
trated by one study.31 A cardiac arrest was reported during
exercise although no obstructive CAD was found during
prior testing. Cardiac screening may therefore create a false
sense of safety. Moreover, CPET itself also harbors a risk of
cardiac complications. Approximately one to ﬁve complica-
tions per 10,000 tests were reported,27,32 a percentage that
clearly exceeds any risk caused by SET.
Some have suggested that CPET is useful in detecting
silent ischemia.33 Because most patients with IC will expe-
rience myocardial ischemia as anginal pain during exertion,
some 17% to 47% will be asymptomatic (ie, silent ischemia
type I).34 Extensive research has been done in patients with
diabetes mellitus, a condition associated with an even
higher prevalence of silent ischemia.35 A difference bet-
ween silent and symptomatic CAD with respect to prog-
nosis was never found.34,36,37 Patients with IC may
potentially beneﬁt from routine CAD screening through
detection of silent ischemia; however, considering the
high prevalence of silent ischemia and assuming that these
patients were also present in our review, a larger number of
incidents would have been expected. The value of CPET is
therefore also questionable from this perspective.
Lastly, CPET is potentially useful as a tool allowing for
training optimization. A recent review attempted to iden-
tify the most important exercise components resulting in
an optimal training protocol for patients with IC. The
study concluded that intensity, duration, and program con-
tent were not independently associated with improvement
of maximal of pain-free walking distance.25 Therefore, sel-
ection of SET components based on CPET does not seem
to be a useful strategy.
Our study has limitations associated with its retrospec-
tive methodology and the possibility of publication bias.
Only 35 of 74 studies explicitly reported the possible
occurrence of adverse events, whereas a detailed descrip-
tion was sometimes lacking. Therefore, it remains uncertain
whether all reported events indeed occurred during SET.
JOURNAL OF VASCULAR SURGERY
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missed. However, these were most likely minor events pre-
venting the patient from stopping any activity. By our strat-
egy of using information on dropouts, the number of
patient-hours was increased as was the chance on some
extra uncertainty.
The included studies were very heterogenic in content
of the SET program, and an exact description of intensity
was often lacking. Therefore, identifying any potential asso-
ciation between intensity of SET and complication risk was
not possible. Subgroup analyses were impossible due to the
small number of adverse events. An additional disadvantage
of the present study is that the most of the participants
were men. Consequently, the safety of SET is not demon-
strated in female IC patients, although gender differences
regarding the response to SET were never reported.
A major methodologic concern is that some studies
excluded patients with limited exercise capacity due to
angina, heart failure, chronic obstructive pulmonary dis-
ease, arthritis, poorly controlled hypertension, or recent
myocardial infarction. Exclusion of these vulnerable cardiac
patients might have resulted in an underestimation of the
number of adverse events. Therefore, generalizing these
results to IC patients with major comorbidities is hazard-
ous. On the other hand, one must appreciate that exercise
training also reduces the all-cause mortality in patients with
congestive heart failure by 11%.38 Others demonstrated in
patients with stable CAD that a 12-month program of reg-
ular physical exercise resulted in superior event-free survival
and exercise capacity compared with percutaneous coro-
nary angioplasty (88% vs 70%; P ¼ .023).39 As a conse-
quence, patients with (cardiac) comorbidity should not
routinely be excluded from SET in daily practice. However,
each patient obviously requires careful monitoring.
CONCLUSIONS
The present review demonstrates that SET can safely
be prescribed in IC patients because cardiovascular compli-
cation rates associated with this type of therapy are
extremely low. However, caution should be taken when
applying these results in patients with major comorbidity.
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